Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
Aytu BioPharma Highlights Opportunity for EXXUATM as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
Aytu BioPharma Announces Commercial Availability of EXXUA Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
Element79 Announces Extension to Proposed Spin Out and Merger, Mailing of Meeting Materials for Special Meeting in Connection with Previously Announced Plan of Arrangement with Synergy Metals Corp.
German Federal Ministry for Economic Affairs and Energy Officially Opens HyProMag Second Plant in Pforzheim, Germany
LaFleur Minerals Acquires McKenzie East Gold Project Expanding Val-d'Or Gold Portfolio; Advances Aggressive Drilling at Swanson Gold Project
